Top of this page
Skip navigation, go straight to the content
Posted by
26-Jun-2014
Posted by HM, 01 October 2014 The Bank's “at risk co-development funding” will make up to €75 million available for the development of which selected UCB compounds, in particular?
Posted by UCB While I’m not at liberty to disclose the specific names of the compounds, I can share that the EIB funding concerns 6 projects from our pipeline in both immunology and neurology, and at various stages of development. For more information don’t hesitate to contact me at laurent.schots@ucb.com
Leave a Comment